Illumina Continues to Build on Infinium Assay with New Sanger Agreement | GenomeWeb

Illumina will take advantage of a new agreement with the Wellcome Trust Sanger Institute and the Wellcome Trust Case-Control Consortium to develop a new custom BeadChip that will become commercially available after the Sanger completes its studies using the chip next year, Illumina said last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.